Residues energetically linked to the allosteric transition of thrombin from its anticoagulant slow form to the procoagulant fast form have been identified by sitedirected mutagenesis. The energetics of recognition by the two forms of the enzyme were probed by using a synthetic chromogenic substrate, fibrinogen, and hirudin. The thrombin residues E39, W60d, E192, D221, and D222 are linked to the slow --fast transition and are part of an "allosteric core" through which events originating at the Na+ binding loop propagate to other regions of the enzyme. The thrombin residues Y76, W96, W148, and R173 lie at the periphery of the allosteric core, affect recognition of fibrinogen and hirudin to the same extent in both forms, and are not linked to the slow -> fast transition.
Thrombin is an allosteric enzyme existing in two forms, slow and fast (1), that have been targeted toward two important and opposite roles (2) . The slow form is anticoagulant because it activates more specifically protein C, a potent inhibitor of blood coagulation. The fast form is procoagulant because it cleaves fibrinogen with higher specificity and promotes formation of a blood clot. Much of the control of thrombin function in hemostasis can be reduced to the control of the allosteric equilibrium between the slow and fast forms. Identification of the structural components that are energetically linked to the slow -> fast transition is therefore crucial for unraveling structure-function relationships and may eventually lead to innovative strategies for control of thrombin function in vivo.
Identification of residues energetically linked to the allosteric transitions of thrombin is based on the properties of the following thermodynamic cycle (3) AGO S <==> F AGs :a :a&Gf[1 SL *' FL AG1
The slow (S) and fast (F) forms bind a ligand (L) with a standard free energy AGs and AGf, while AGO and AG1 reflect the standard free energy changes for switching from the slow to the fast form in the absence and presence of the ligand. The coupling free energy in the cycle is given by AGc= AGf-AGs = AG'-AGO [2] and measures the difference in binding free energy between the fast and slow forms. The value of AGc is negative if the fast form binds with higher affinity and is positive otherwise.
Residues energetically linked to the slow -* fast transition can be mapped from the effect of their mutation on the value of AGc.
The foregoing approach developed for the study of recognition processes in cooperative systems (4) bears conceptually on recent analyses of mutational effects in proteins (5) and is also amenable of extension to the analysis of substrate binding in the transition state. In this case, the vertical edges in the thermodynamic cycle 1 represent the free energies of formation of the transition state in the slow and fast forms. The coupling free energy in the transition state is (4) AG* =,AG' -AGO = -RTln (ka/K) K) 3 and depends on the specificity constants of the fast and slow forms. Residues energetically linked to the slow --fast transition in the transition state can be mapped from the effect of their mutation on the value of AG*. Perturbation due to the mutation is quantified by the expression (4, 6) LAG* = RTln (kcat/Km)wt I41 (kcat/Km)mut which applies to both the slow and fast forms.
The slow --fast transition is induced by binding of a Na+ ion (7) and can be studied with a number of substrates used as probes of the energetics pertaining to the structural domains to which they bind. Regions important for recognition of S2238 (8) , fibrinogen (9) , and hirudin (10) were targeted by sitedirected mutagenesis and the energetics were assessed by using the thermodynamic cycle 1.
MATERIALS AND METHODS
Human a-thrombin was purified and tested for activity as described (1-3). Recombinant desulfatohirudin variant 1 (Revasc) was obtained from CIBA-Geigy. The concentration of hirudin was determined by amino acid analysis and titration (2) . Human fibrinogen was purchased from Hematologic Technologies (Essex Junction, VT) and was purified and tested for activity as described (2) . The chromogenic substrate S2238 (H-D-Phe-pipecolyl-Arg-p-nitroanilide) was purchased from Chromogenix (Molndal, Sweden).
The pNUT-hGH expression vector was obtained from Richard Palmiter (University of Washington, Seattle) and the pIIH13 plasmid was obtained from Ross MacGillivray (University of British Columbia, Vancouver). Constructs were made in the laboratory of Charles Esmon (Oklahoma Medical Research Foundation, Oklahoma City). The E192Q, Y76A, and W96A mutations were obtained by oligonucleotidedirected mutagenesis in M13 phage (11, 12) carried out by the primer-extension method (13) and the dut-ung-selection method (14) . Each Sst I/EcoRI fragment containing the single Abbreviations: FpA, fibrinopeptide A; FpB, fibrinopeptide B. *To whom reprint requests should be addressed.
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[31 Proc. Natl. Acad. Sci. USA 92 (1995) mutation was substituted for the corresponding sequence in pUC13-hII (12) and the Sma I/EcoRI fragment was subsequently substituted for the human growth gene in the pNUThGH vector. The Sma I/EcoRI fragment at the 3' end of the prothrombin cDNA contains the polyadenylylation signal of the growth hormone gene from the original pNUT-hGH vector (15) . The E39Q, W60dS, W148S, R173E, and D221A/ D222K mutations were obtained by amplification of either the Sst I/Bgl II or Bgl Il/EcoRI sequences of pNUT-hII (12) with appropriate primers for the polymerase chain reaction. Recombinant prothrombins E39Q and E192Q were expressed in baby hamster kidney cells (BHK21) with the pNUT vector. The other mutations were expressed as prethrombin 1 using the pNUT vector constructed with the bovine factor V signal peptide and a 12-amino acid HPC4 epitope (16) . The recombinant prothrombin mutants were isolated by affinity chromatography using the human prothrombin-specific monoclonal antibody hPT959 coupled to AffiGel 15 (Bio-Rad). Recombinant prethrombin 1 mutants preceded by a 12-amino acid HPC4 epitope were purified on an HPC4 AffiGel 10 column. The zymogen form was activated and the thrombin form was purified to homogeneity as described (11) . All mutants were titrated and tested for activity with hirudin (2).
Mutations were made over the entire surface of recognition of S2238, fibrinogen, and hirudin, as documented by the crystal structures (8) (9) (10) . Four regions of thrombin were targeted for mutagenesis. The W60d loop (W6OdS), containing the specificity subsite S2, and the specificity subsite S3 (W96A) were perturbed to assess their contribution to recognition of S2238, fibrinopeptide A (FpA), fibrinopeptide B (FpB), and hirudin. The W148 loop (W148S) and the fibrinogen binding loop (E39Q, Y76A) were targeted to perturb recognition of FpA, FpB, and hirudin. The Na+ binding loop (D221A/D222K) was perturbed to interfere with the binding of Na+ and the slow -> fast transition by altering the negative electrostatic potential at the site. D221 and D222 flank R221a, which donates its carbonyl oxygen to the coordination shell of the bound Na+ (7). The double replacement D221A/D222K mimics the sequence found in factor Xa, which has a reduced Na+ affinity compared to thrombin. Mutations of E192 (E192Q) and R173 (R173E) were also made. E192 is involved in the switch of thrombin specificity toward protein C (11), while R173 forms a seemingly important salt bridge with D5 of hirudin (10) and Dll of the fibrinogen Aa chain (9) . The properties of the slow and fast forms of thrombin and its mutants were studied under experimental conditions of 5 mM Tris.HCl/O.1% PEG, pH 8.0 at 25°C/200 mM NaCl when studying the fast form or 200 mM choline chloride when studying the slow form. Binding of hirudin, hydrolysis of S2238, and release of FpA and FpB were studied and analyzed as described (1-3). The mechanism of release of fibrinopeptides was found to be the same as that of the wild type for all mutants, and so was the mechanism of hydrolysis of S2238. Product inhibition was negligible in all cases. These findings substantiate the use of Eqs. 3 and 4 (17) .
RESULTS
The relevant properties of the eight mutants analyzed in this study are summarized in Fig. 1 and Table 1. In the case of wild type, the fast form binds hirudin with higher affinity, preferentially cleaves S2238, and releases FpA and FpB with higher specificity. The coupling free energy values for these processes range from -0.8 kcal/mol (1 cal = 4.184 J) in the case of FpB to -1.9 kcal/mol in the case of hirudin. Mutations can in principle affect the way substrates and ligands are recognized by either thrombin form. When the effect on one form predominates, the mutation affects the value of the coupling free energy and indicates that the mutated residue is energetically linked to the slow --fast transition. Mutations that affect both forms to the same extent reveal residues that are important for recognition, but are not energetically linked to the slow --fast transition. The effects of each mutation are discussed in order below. Perturbations of the coupling free energy terms were considered significant only if they were >0.6 kcal/mol (in absolute value), which is the value ofRTunder the experimental conditions used.
The E39Q mutation shows no effect on hydrolysis of S2238, a modest effect on the release of FpA and FpB, but a significant effect on hirudin binding. Perturbation of AG4 (see Table 1 ) is borne out by a decrease in the binding affinity to the fast form and a concomitant increase in affinity for binding to the slow form. The W6OdS mutation has significant effects on all the interactions studied. With the exception of FpB, the coupling free energy values for S2238 hydrolysis, FpA release, and hirudin binding vanish for this mutant. Particularly noteworthy is the differential effect on the release of fibrinopeptides. The mutation affects mostly the release of FpB, which becomes much slower than that of FpA. W60d seems to be a crucial residue for transducing events linked to the slow -> fast transition of the enzyme and is particularly important for recognition of the BP3 chain of fibrinogen. The Y76A mutation shows no effect on hydrolysis of S2238 but a significant effect on the release of FpA and FpB and hirudin binding. The perturbation, however, is practically identical in both allosteric forms and the coupling free energy values remain unaffected. The W96A mutation affects the hydrolysis of S2238 and the release of FpA, but it has no effect on the release of FpB and hirudin binding. Again, the effect is similar in both allosteric forms. The W148S mutation has no significant effect on any of the interactions studied. The R173E mutation shows no effect on the hydrolysis of S2238 and a modest effect on the release of FpA and FpB and hirudin binding. No significant effect is seen on the coupling free energy values. The E192Q mutation perturbs the hydrolysis of S2238 and hirudin binding to the same extent in both allosteric forms, thereby causing no significant changes in AG'* and AG4 (see Table 1 ). The effect on the release of fibrinopeptides is more pronounced in the case of FpA. This makes the value of AG 2 (see Table 1 ) more negative and increases the differences between the fast and slow forms. The double mutation D221A/D222K is intriguing since it decreases specificity and affinity in the fast form, while increasing them in the slow form. The result is a significantly reduced value of the coupling free energy for S2238, FpA, and hirudin.
Hydrolysis of S2238 is affected mostly by mutation of W60d, especially in the fast form, and to a lesser extent by mutation of W96, E192, D221, and D222. Of these residues, only W60d makes direct contacts with the substrate in the specificity pocket S2 (8) . The effect seen on W96 may be due to indirect perturbation of the adjacent specificity subsite S3 (8) . The effects due to mutation of D221 and D222 are also indirect and mediated by perturbation of the slow < fast equilibrium (7).
The release of FpA is much perturbed by mutation of Y76, a residue of the fibrinogen binding loop, and to a lesser extent by mutation of W60d, W96, R173, E192, D221, and D222. Of these residues, W60d and R173 make direct contacts with the fibrinogen Aa chain (9) . In particular, R173 makes a salt bridge interaction with D11 of the fibrinogen Aa chain and has been suggested to play a key role in recognition of this natural substrate (9) . The modest perturbation (0.7 kcal/mol) of the transition state for the release of FpA (see Table 1 Values for wild type (error, c5%) refer tos = kcat/Km (tLM-1s-') or the equilibrium dissociation constantKd (pM). Values of AAG4 were derived from Eq. 4 and AAG4 = RTln(Kdmut/Kdt). Values of AG* and AG4 were derived from Eqs. 3 and 2. Superscripts: 1, S2238; 2, FpA; 3, FpB; 4, hirudin.
Errors are ±0.1 kcal/mol or less. 
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Proc. Natl. Acad. Sci. USA 92 (1995) residues to the transition state is different than that observed for the release of FpA from the Aa chain of fibrinogen.
Binding of hirudin is much perturbed by mutation of W60d and Y76. In the fast form, each of these residues contributes nearly 3.0 kcal/mol toward binding of the inhibitor. The large energetic contribution of these residues is intriguing, since W60d makes minor contacts with I1, K47, and Q49 of hirudin, while Y76 is hydrogen bonded to E57 and makes minor contacts with E58 and P60 of hirudin (10) . In the slow form, mutation of W60d affects hirudin binding to a lesser extent, while mutation of Y76 drops the affinity by nearly the same extent as in the fast form. As a result, mutation of W60d completely abolishes preferential binding of hirudin to the fast form, while Y76 has no effect on the value of AG4 (see Table 1 ). Mutations of E39, D221, and D222 decrease the affinity of the fast form slightly and increase the affinity of the slow form more markedly. As a result, the value of AGC (see Table 1 ) is significantly perturbed and preferential binding to the fast form is almost entirely abolished. E39 is salt-bridged to H51 of hirudin in the fast form (10) . However, mutation of this residue perturbs the free energy of hirudin binding to the fast form by only 0.4 kcal/mol. This finding is in agreement with mutagenesis studies of hirudin that have reported only a modest perturbation of hirudin affinity for the H51Q mutant (20) . As to D221 and D222, these residues make no direct contacts with hirudin and therefore the effect seen upon mutation is indirect and mediated by a perturbation of the slow <--fast equilibrium (7) . Mutations of R173 and E192 perturb binding to both forms to the same extent, with no significant changes in the value of AG4 (see Table 1 ). The extent of energetic perturbation is consistent with the crystal structure in the case of E192 but not R173. In fact, E192 makes only minor contacts with T2, T4, and S50 of hirudin, while R173 is salt-bridged to E17. As in the case of fibrinogen (see above), functional studies do not support the importance of R173 as implied by the crystal structure (9, 10) . Mutation of W96 or W148 does not affect binding of hirudin. This is consistent with the crystal structure since W148 makes no contacts with the inhibitor, while W96 makes only a minor contact with K24 of hirudin.
DISCUSSION
Structural domains of thrombin can be probed energetically by using specific ligands, substrates, and effectors. Analysis of the perturbation pattern for each case reveals thrombin residues energetically involved in the recognition mechanism and linked to the allosteric transitions of the enzyme. Recognition of fibrinogen shows aspects unanticipated by crystallographic analysis (9) . The salt-bridge between R173 and E1i of the Aa chain of fibrinogen seems to make only a modest contribution to formation of the transition state for FpA release. Mutation of Y76 perturbs the release of FpA significantly and has a less pronounced effect on the release of FpB. The opposite effect is seen upon mutation of W60d. Hence, Y76 and W60d seem to be directly involved in fibrinogen recognition. In addition, W96 plays a key role in the release of FpA, but not FpB, and the same is true for E192 in the slow form. Mutation of D221 and D222 in the Na+ binding loop perturbs the release of FpA and FpB indirectly. Hydrolysis of S2238 is affected mostly by mutation of W60d and W96, two residues in and around the specificity subsites S2 and S3, while the effect seen upon mutation of D221 and D222 is again indirect. In the case of hirudin, W60d and Y76 play a crucial role in recognition, as seen for the release of FpA, while W96 plays no role. Other important residues are E39, R173, E192, D221, and D222.
Mutations of E39, W60d, E192, D221, and D222 significantly affect the coupling free energy for allosteric switching in the thermodynamic cycle 1. With the exception of E192, these mutations reduce the differences between the slow and by decreasing the affinity in the fast form and increasing the affinity in the slow form. This dual effect is even more evident with mutation of D221 and D222 that practically abolishes the energetic differences between the two forms. The two forms tend to become energetically equivalent also upon mutation of W60d but for a different reason. In this case, specificity is reduced in both forms but more so in the fast form. Mutation of E192 increases the differences between the two forms in the release of FpA by destabilizing the transition state in the slow form.
A MOLSCRIPT plot (21) of thrombin is shown in Fig. 2 . The residues energetically linked to the slow --fast transition are marked in red at the Co atom, while those not linked are marked in blue. The linked residues are part of an allosteric core defined by portions of the Na+ binding loop (D221 and D222), the W60d loop (W60d), and the environment of E192 and E39. The residues not linked to the allosteric transition (Y76, W96, W148, R173) lie at the periphery of the allosteric core. This core provides the structural network enabling the Na+ binding loop to communicate energetic changes to the catalytic pocket of the enzyme and to distant regions like the fibrinogen binding loop (1-3). A complete mapping of the allosteric core by further mutagenesis and functional studies, along the lines introduced here, will unravel the code for structure-function relationships of thrombin and provide means of exploiting the allosteric equilibrium between the slow and fast forms for therapeutic purposes. 
